Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma

Patients with cutaneous T cell lymphoma experience refractory and progressive disease despite current treatment, necessitating chronic disease management. In addition, there needs to be greater emphasis on combination treatment, which correlates with increased response rate, more rapid onset of response, and decreased side effect profile compared to monotherapy. The goal …

cancer
treatment regimen
bexarotene
lenalidomide
mycosis
  • 112 views
  • 08 Nov, 2020
  • 1 location
Multi-center Trial of Revlimid and Rituximab for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

The study is a two-arm, multi-center trial of Revlimid® and Rituximab, for the frontline treatment of patients with Chronic Lymphocytic Leukemia (CLL) designed and conducted by the CLL

revlimid
cancer
rituximab
lymphoid leukemia
lenalidomide
  • 42 views
  • 07 Nov, 2020
  • 3 locations
Study of SubQ Dara With Dose-Attenuated Bortezomib Lenalidomide Dexamethasone in Elderly NDMM

daratumumab, dose-attenuated bortezomib, revlimid, and dexamethasone until confirmed disease progression, discontinuation of study treatment due to unacceptable drug toxicity, or other reasons. Throughout the

  • 1 views
  • 28 Jan, 2021
  • 1 location
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

To characterize safety associated with the use of Kyprolis under the locally approved label.

  • 0 views
  • 26 Aug, 2021
  • 26 locations
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide

bortezomib
dexamethasone
lenalidomide
neutrophil count
cell transplantation
  • 14 views
  • 30 Jul, 2021
  • 38 locations
Venetoclax Ibrutinib Prednisone Obinutuzumab and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Background B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR). Objective To study …

g-csf
flow cytometry
ibrutinib
mantle cell lymphoma
lenalidomide
  • 69 views
  • 12 Sep, 2021
  • 1 location
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.

g-csf
therapeutic regimen
kappa light chain
ibrutinib
daratumumab
  • 2 views
  • 22 Jun, 2021
  • 5 locations
Carfilzomib Lenalidomide and Dexamethasone Versus Bortezomib Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)

This is a randomized multicenter study that will compare two treatment regimens (Kyprolis, Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with newly

electrophoresis
bortezomib
serum proteins
dexamethasone
lenalidomide
  • 71 views
  • 14 Jun, 2021
  • 1 location
Venetoclax Ibrutinib Prednisone Obinutuzumab and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Background Aggressive B-cell lymphomas can be cured but people with disease that resists treatment or that returns after treatment have poor outcomes with standard therapies. Indolent B-cell lymphomas are generally incurable with standard therapy and treatment is aimed at controlling symptoms and achieving a durable remissions. Researchers want to see …

g-csf
cancer
flow cytometry
ibrutinib
neutrophil count
  • 0 views
  • 12 Sep, 2021
  • 1 location
DARA RVD For High Risk SMM

The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating

bortezomib
cancer
velcade
anemia
bone marrow procedure
  • 0 views
  • 22 Aug, 2021
  • 2 locations